#USA #Redwood City #medical technology #Galvanize Therapeutics #Laura Francis

Galvanize Therapeutics Welcomes Laura Francis to Board of Directors

Introduction
Galvanize Therapeutics, Inc., renowned for its innovative pulsed electric field (PEF) therapies targeting oncology and chronic lung diseases, has announced the addition of Laura Francis to its Board of Directors. This strategic move aims to bolster the company's leadership as it continues to advance its pioneering technologies.

About Laura Francis
Laura Francis is a seasoned executive in the medical technology sector, currently serving as the Chief Executive Officer and Board member at SI-BONE, Inc., where she focuses on addressing musculoskeletal disorders. Her extensive background includes crucial roles at Auxogyn, now part of Progyny, Promega Corporation, and Bruker Corporation. Furthermore, she has been instrumental as an Engagement Manager with McKinsey & Company and as an Audit Manager at PricewaterhouseCoopers (formerly Coopers & Lybrand).
Her experience spans both public and private life science companies, allowing her to provide invaluable insights and guidance in financial governance and operational strategy.

Francis's Contributions to Galvanize
As Galvanize Therapeutics embarks on its next phase of growth, the expertise that Francis brings is expected to be pivotal. Her connection to Galvanize’s Chairman and CEO, Doug Godshall, enriches this partnership. Godshall emphasized that Laura’s proven track record in fostering innovative, high-growth medical technology companies aligns perfectly with Galvanize’s mission to enhance patient care through advanced therapies.

The Importance of This Appointment
Her appointment comes at a critical juncture for Galvanize, as the company works on scaling its commercial operations and further developing its technical and clinical portfolios. Galvanize aims to make its transformative therapies accessible to a wider audience, specifically targeting those suffering from conditions inadequately addressed by contemporary treatments. The collaboration between Godshall and Francis signals a robust approach toward navigating the complexities of the healthcare landscape.

Galvanize’s Vision and Future Plans
Galvanize Therapeutics envisions itself as a leader in delivering medical technology innovations, specifically focused on treating a variety of diseases like solid tumors and chronic bronchitis. The company, headquartered in Redwood City, California, is in the process of commercializing its Aliya® PEF energy platform, a groundbreaking therapy that holds promise for many patients across the United States.

Educational Background
Laura holds a Bachelor of Business Administration in Accounting and Finance from the University of Wisconsin and an MBA from Stanford University. Her academic credentials, combined with her extensive industry experience, render her a valuable asset to Galvanize’s strategic objectives.

Conclusion
As Galvanize Therapeutics prepares for a future with expanded operations and cutting-edge therapies available to patients, Laura Francis's role on the Board of Directors will be instrumental. Her leadership and industry knowledge will undoubtedly aid the company in its mission to innovate healthcare solutions and improve patient outcomes.

For More Information
For more details about Galvanize Therapeutics and their work, visit www.galvanizetx.com.